you are here: HomeNewsTrendsHealth

Cipla gets USFDA nod for inhalation product

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing.

June 23, 2021 / 12:04 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Cipla on Wednesday said it has received final approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market.

The approved product is a generic version of Sunovion Pharmaceuticals Inc's Brovana.

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation  Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Quoting IQVIA (IMS Health) data, Cipla said Brovana had US sales of approximately USD 438 million for the 12-month period ending April 2021.

Close
The product is available for shipping immediately, it added.
PTI
first published: Jun 23, 2021 12:03 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark